Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

NCT05616221 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-cystic Fibrosis Bronchiectasis
Pseudomonas Aeruginosa
Lung Infection

Interventions

BIOLOGICAL: AP-PA02
OTHER: Placebo

Sponsor

Armata Pharmaceuticals, Inc.